RightAnswer Knowledge Solutions Search Results for Aldesleukin

New Search  |  Search Results (Aldesleukin)  |  Index of Example Chemical Results Pages
register now
RightAnswer Knowledge Solutions provides access to hundreds of data sources. Our premier and proprietary sources include fully-researched documents from well-established experts in the chemical and HazMat fields.

A search in our system for this chemical would return results – all in one place -- in the following categories from the listed data sources.
  • Chemical Identification
  • Environmental Hazards
  • First Aid/Medical Treatment
  • Physical/Chemical Properties
  • Regulatory/Standards/Labels
  • Report Abstracts and Studies
  • Reproductive Risk
  • Toxicology/Health Hazards/Exposure
Example of Acute Exposure data from MEDITEXT.

RightAnswer Proprietary Data Sources:

MEDITEXT® Documentshelp


All Other Data Sources:

DART Documentshelp
LOLI® Listingshelp
REPROTOX® Documentshelp
RTECS® Registryhelp
Shepard's Cataloghelp
MSDSonline®help

ChemID External Links:


Other Government Links Searched via RegsKnowledge:

State Environmental Regulationshelp
CFR Regulationshelp

Example Content from MEDITEXT for Aldesleukin:


Please note: this is an extract of information from a larger document. Full document and details are available by subscription.

ACUTE EXPOSURE INFORMATION

  1. WITH THERAPEUTIC USE
    1. Capillary leak syndrome usually develops within a few hours of the start of aldesleukin (IL-2) therapy and begins to resolve within a few hours of its discontinuation. Common manifestations include hypotension, tachycardia and oliguria. Generalized edema, weight gain, pleural effusions, pulmonary edema, ascites, renal insufficiency and confusion may also develop.
    1. Nausea, vomiting and diarrhea develop in most patients and diarrhea may be severe. Anemia, leukopenia and thrombocytopenia may develop but are rarely severe. Fever and chills are also common during therapy.
    1. Increased serum bilirubin is common, increased aminotransferase levels develop less often and both usually resolve after therapy is discontinued. Electrolyte disturbances (hypomagnesemia, hypocalcemia, hypokalemia, and hypophosphatemia) develop in about 10% of patients but are rarely severe.
  1. WITH POISONING/EXPOSURE
    1. Overdose information is limited. Exceeding the recommended dose has ben associated with a more rapid onset of typical adverse effects.
© 2011-2017 RightAnswer.com, Inc. and/or its licensors. All rights reserved. No claim to original U.S. Govt. works.